The most-cited Articles on
Astrocytomas

Elarjani T, et al., Bibliometric analysis of the top 100 most-cited articles on astrocytoma.
Surg Neurol Int. 2021


Home > Publications > The most-cited articles > Diffuse astrocytic and oligodendroglial tumors > Brown NJ, 2020


Contents

Elarjani T, Almutairi OT, Alhussinan M, Alzhrani G, Alotaibi FE, Bafaquh M.
Bibliometric analysis of the top 100 most-cited articles on astrocytoma.
Surg Neurol Int. 2021 Feb 17;12:62
. doi: 10.25259/SNI_521_2020. PMID: 33654565. Bibliometric analysis.




Case reports


Classification


Diagnosis, Presentation


Epidemiology, Risk factors


Etiology, Pathogenesis, Pathology


Follow-up, Side effects, Quality of life


Integrative medicine


Overall management


Prognosis, Outcomes


Treatment



Case reports





Classification





Diagnosis, Presentation





Epidemiology, Risk factors






Etiology, Pathogenesis, Pathology

Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM.
p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.
Cancer Res. 1992 Feb 1;52(3):674-9. PMID: 1346255. Laboratory investigation.



Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P, Pfister SM; International Cancer Genome Consortium PedBrain Tumor Project.
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
Nat Genet. 2013 Aug;45(8):927-32. doi: 10.1038/ng.2682. Epub 2013 Jun 30. PMID: 23817572. Laboratory investigation.



Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY.
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
J Clin Invest. 1997 Mar 15;99(6):1173-8. doi: 10.1172/JCI119273. PMID: 9077524. Laboratory investigation.



Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A.
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
Acta Neuropathol. 2011 Mar;121(3):397-405. doi: 10.1007/s00401-011-0802-6. Epub 2011 Jan 29. PMID: 21274720. Laboratory investigation.



Watanabe T, Nobusawa S, Kleihues P, Ohgaki H.
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Am J Pathol. 2009 Apr;174(4):1149-53. doi: 10.2353/ajpath.2009.080958. Epub 2009 Feb 26. PMID: 19246647. Laboratory investigation.



Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF.
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.
Cancer Cell. 2005 Aug 1;8(2):119-30. doi: 10.1016/j.ccr.2005.07.004. PMID: 16098465. Laboratory investigation.



Follow-up, Side effects, Quality of life





Overall management





Prognosis, Outcomes

Burger PC, Vogel FS, Green SB, Strike TA.
Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications.
Cancer. 1985 Sep 1;56(5):1106-11. doi: 10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2. PMID: 2990664. Retrospective analysis.



McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quiñones-Hinojosa AR.
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
J Neurosurg. 2009 Jan;110(1):156-62. doi: 10.3171/2008.4.17536. PMID: 18847342. Retrospective analysis.



Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB.
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.
J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56. doi: 10.1093/jnci/93.16.1246. PMID: 11504770. Laboratory investigation.



Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB.
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
J Clin Oncol. 2000 Feb 1;18(3):636-45. doi: 10.1200/JCO.2000.18.3.636. PMID: 10653879. Laboratory investigation.



Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG.
Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.
Int J Radiat Oncol Biol Phys. 1989 Jun 1;16(6):1405-9. doi: 10.1016/0360-3016(89)90941-3. PMID: 2542195. Retrospective analysis.



Treatment

Bleehen NM, Stenning SP.
A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party.
Br J Cancer. 1991 Oct 1;64(4):769-74. doi: 10.1038/bjc.1991.396. PMID: 1654987. Randomized trial.



Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, et al.
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.
J Clin Oncol. 1995 Jan 1;13(1):112-23. doi: 10.1200/JCO.1995.13.1.112. PMID: 7799011. Phase 3 trial.



Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)61134-9. Epub 2012 Nov 14. PMID: 23158522. Phase 3 trial.
Erratum in: Lancet. 2013 Jan 12;381(9861):116. doi: 10.1016/S0140-6736(13)60050-1. Correction.



Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR.
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.
Ann Neurol. 2006 Mar;59(3):490-8. doi: 10.1002/ana.20784. Epub 2006 Feb 17. PMID: 16453317. Pilot study.



Laws ER Jr, Taylor WF, Clifton MB, Okazaki H.
Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres.
J Neurosurg. 1984 Oct;61(4):665-73. doi: 10.3171/jns.1984.61.4.0665. PMID: 6470776. Retrospective analysis.



Thomas D, et al., Medical Research Council Brain Tumor Working Party.
Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.
J Clin Oncol. 2001 Jan 15;19(2):509-18. doi: 10.1200/JCO.2001.19.2.509. PMID: 11208845. Randomized trial.



van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB; EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council.
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
Lancet. 2005 Sep 17-23;366(9490):985-90. doi: 10.1016/S0140-6736(05)67070-5. Epub 2005 Aug 18. PMID: 16168780. Randomized trial.
Erratum in: Lancet. 2006 Jun 3;367(9525):1818
. doi: 10.1016/S0140-6736(06)68803-X. Correction.



Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society.
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Lancet Oncol. 2012 Jul 1;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10. PMID: 22578793. Phase 3 trial.



Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA.
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
J Clin Oncol. 1999 Sep 1;17(9):2762-71. doi: 10.1200/JCO.1999.17.9.2762. PMID: 10561351. Phase 2 trial.
Erratum in: J Clin Oncol 1999 Nov 1;17(11):3693. doi: 10.1200/JCO.1999.17.11.3693. Correction.







20◽a


Bottom